Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567580 · ClinicalTrials.gov registry record · Phase 3
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.
- Active
- Registry status
- Phase 3
- Development phase
- 1,792
- Enrollment target
- 20
- Study locations
NCT00567580 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by Radiation Therapy Oncology Group. The registered enrollment target is 1,792 participants, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (196% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00567580, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by Radiation Therapy Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,792 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone agonist, may lessen the amount of androgens made by the body. It is not yet known which regimen of radiation therapy with or without androgen-deprivation therapy is more effective for prostate cancer. PURPOSE: This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer.
Conditions Studied
Interventions
- DRUG LHRH agonist
- RADIATION PBRT
- RADIATION PLNRT
- DRUG AA
Study Locations (20)
California
- Auburn Radiation Oncology - Auburn
- Peninsula Medical Center - Burlingame
- Radiation Oncology Centers - Cameron Park - Cameron Park
- Mercy Cancer Center at Mercy San Juan Medical Center - Carmichael
- East Bay Radiation Oncology Center - Castro Valley
- Valley Medical Oncology Consultants - Castro Valley - Castro Valley
- Enloe Cancer Center at Enloe Medical Center - Chico
- Valley Medical Oncology - Fremont
- Washington Township Hospital - Fremont
- California Cancer Center - Woodward Park Office - Fresno
- Cancer Care Associates - Fresno
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Veterans Affairs Medical Center - Long Beach - Long Beach
- Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center - Los Angeles
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
Arizona
- Arizona Center for Cancer Care - Peoria - Peoria
- Arizona Oncology Services Foundation - Phoenix
- Arizona Oncology - Tucson - Tucson
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Alaska
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital - Fairbanks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,792 participants |
| Start Date | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00567580
The ClinicalTrials.gov registry entry for NCT00567580 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,792 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (196% higher). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which LHRH agonist is the first listed.
NCT00567580 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00567580 about?
NCT00567580 is a clinical study titled "Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone agonist, may lessen the amount of androgens made by the body. It is not y...
What is the current status of trial NCT00567580?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,792 participants. The study started on 2008-02.
What conditions does trial NCT00567580 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00567580?
The interventions under investigation include: LHRH agonist (DRUG), PBRT (RADIATION), PLNRT (RADIATION), AA (DRUG).
Who is sponsoring clinical trial NCT00567580?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00567580 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.